Infections are an intriguing new frontier for monoclonal antibody drugs, which have shown success thus far in treating cancer and autoimmune disease.
Arsanis, a startup based in Massachusetts and Austria, just closed out a $45.5 million Series D, led largely by the Bill & Melinda Gates Foundation. The company’s in Phase 2 trials, testing out its experimental biologic as a tool to prevent pneumonia in high-risk patients. It’s also developing a companion diagnostic.
About the Author Reprints
